ZLAB Zai Lab Ltd
Price (delayed)
$29.71
Market cap
$3.21B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.6
Enterprise value
$2.81B
Zai Lab ) is an innovative commercial stage biopharmaceutical company focused on bringing transformative medicines for cancer, infectious and autoimmune diseases to patients in China and around the world. To
Highlights
Zai Lab's revenue has increased by 50% YoY and by 12% from the previous quarter
ZLAB's gross profit is up by 47% year-on-year and by 12% since the previous quarter
The quick ratio is down by 24% year-on-year but it is up by 18% since the previous quarter
The debt has grown by 22% from the previous quarter
Key stats
What are the main financial stats of ZLAB
Market
Valuations
Earnings
Shares outstanding
108.08M
Market cap
$3.21B
Enterprise value
$2.81B
Price to earnings (P/E)
N/A
Price to book (P/B)
3.52
Price to sales (P/S)
7.37
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.05
Revenue
$398.99M
Gross profit
$251.13M
Operating income
-$276.82M
Net income
-$257.1M
EBIT
-$254.85M
EBITDA
-$234.57M
Free cash flow
-$220.5M
Per share
Balance sheet
Liquidity
EPS
-$2.6
EPS diluted
-$2.6
Free cash flow per share
-$2.23
Book value per share
$8.44
Revenue per share
$4.03
TBVPS
$11.39
Total assets
$1.19B
Total liabilities
$344.86M
Debt
$153.47M
Equity
$840.9M
Working capital
$751.1M
Debt to equity
0.18
Current ratio
3.51
Quick ratio
3.24
Net debt/EBITDA
1.69
Margins
Efficiency
Dividend
EBITDA margin
-58.8%
Gross margin
62.9%
Net margin
-64.4%
Operating margin
-69.4%
Return on assets
-24.8%
Return on equity
-34.6%
Return on invested capital
-164.2%
Return on capital employed
-28.8%
Return on sales
-63.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ZLAB stock price
How has the Zai Lab stock price performed over time
Intraday
3.02%
1 week
-5.74%
1 month
-15.33%
1 year
111.16%
YTD
13.44%
QTD
-17.79%
Financial performance
How have Zai Lab's revenue and profit performed over time
Revenue
$398.99M
Gross profit
$251.13M
Operating income
-$276.82M
Net income
-$257.1M
Gross margin
62.9%
Net margin
-64.4%
Zai Lab's revenue has increased by 50% YoY and by 12% from the previous quarter
The net margin has grown by 49% YoY and by 15% from the previous quarter
The company's operating margin rose by 49% YoY and by 25% QoQ
ZLAB's gross profit is up by 47% year-on-year and by 12% since the previous quarter
Growth
What is Zai Lab's growth rate over time
Valuation
What is Zai Lab stock price valuation
P/E
N/A
P/B
3.52
P/S
7.37
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.05
The EPS has grown by 26% YoY and by 3.7% from the previous quarter
The stock's P/B is 30% below its 5-year quarterly average of 4.9 but 22% above its last 4 quarters average of 2.8
The equity has grown by 26% from the previous quarter and by 6% YoY
ZLAB's price to sales (P/S) is 89% lower than its 5-year quarterly average of 65.4 but 21% higher than its last 4 quarters average of 5.9
Zai Lab's revenue has increased by 50% YoY and by 12% from the previous quarter
Efficiency
How efficient is Zai Lab business performance
Zai Lab's return on invested capital has surged by 65% QoQ and by 40% YoY
The ROS has grown by 49% YoY and by 16% from the previous quarter
The ROA has grown by 19% YoY and by 8% from the previous quarter
ZLAB's ROE is up by 7% YoY and by 6% QoQ
Dividends
What is ZLAB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ZLAB.
Financial health
How did Zai Lab financials performed over time
The company's total liabilities rose by 44% YoY and by 9% QoQ
The current ratio has contracted by 24% YoY but it has grown by 17% from the previous quarter
The debt is 82% less than the equity
The equity has grown by 26% from the previous quarter and by 6% YoY
The debt has grown by 22% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.